DoW Breast Cancer, Transformative Breast Cancer Consortium Development Award
Agency: Dept. of the Army -- USAMRAA
Assistance Listings: 12.420 -- Military Medical Research and Development
Description
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Development Award provides successful applicants the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP Transformative Breast Cancer Consortium Award (pending availability of funds). All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.
Distinctive Features:
· This is a development award and is a separate award mechanism from the full FY26 BCRP Transformative Breast Cancer Consortium Award (HT942526BCRPTBCCA). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms.
· Breast cancer consumer advocates must be active participants in the development and execution of the FY26 BCRP TBCCDA.
Eligibility
Eligible applicants
Miscellaneous
- Unrestricted
Additional information
Grantor contact information
Description
eBRAP Help Desk
Documents
| File name | Description | Last updated |
|---|---|---|
| HT942526BCRPTBCCDA_GG.pdf | FY26 BCRP TBCCDA Program Announcement | May 5, 2026 06:37 PM UTC |
Link to additional information
--
Closing: July 8, 2026
Award
$140,000
Program Funding
1
Expected awards
$--
Award Minimum
$--
Award Maximum
Funding opportunity number:
HT942526BCRPTBCCDA
Cost sharing or matching requirement:
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
Category of Funding Activity:
Science technology and other research and development
Category Explanation:
History
Version:
1
Posted date:
May 4, 2026
Archive date:
August 7, 2026
